AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35298203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCT) delivery by counselors
Number of subjects: 48
Study 35298203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCT) receipt by clients
Number of subjects: 48
Study 35298210 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe tinnitus
Number of subjects: 112
Study 35298210 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus-related distress factors
Number of subjects: 112
Study 35298210 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlational analyses
Number of subjects: 112
Study 35298296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg once daily plus nivolumab 240 mg once every 2 weeks (Cohort 1)
Number of subjects: 47
Study 35298296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg once daily plus nivolumab 480 mg once every 4 weeks (Cohort 1)
Number of subjects: 47
Study 35298296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab (Cohort 2)
Number of subjects: 47
Study 35298296 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 47
Study 35298394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile survey (n=63)
Number of subjects: 127
Study 35298394 — intervention group
Group type: COMPARATOR
Intervention: Bidirectional SMS text messaging (n=64)
Number of subjects: 127
Study 35298514 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Number of subjects: 93
Study 35298514 — intervention group
Group type: COMPARATOR
Intervention: Implementation as Usual (IU)
Number of subjects: 93
Study 35298514 — intervention group
Group type: EXPERIMENTAL
Intervention: MISSION-Vet services
Number of subjects: 93
Study 35298514 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of MISSION-Vet sessions
Number of subjects: 93
Study 35298698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W (Phase 1)
Number of subjects: 58
Study 35298698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrelimab 240 mg Q2W (Phase 2)
Number of subjects: 58
Study 35299035 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (second-line treatment)
Number of subjects: 280
Study 35299035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (third or fourth-line treatment)
Number of subjects: 280
Study 35299248 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) of transmitted/founder viruses
Number of subjects: 355
Study 35299248 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype B isolates
Number of subjects: 355
Study 35299248 — intervention group
Group type: EXPERIMENTAL
Intervention: RC measurement
Number of subjects: 355
Study 35299273 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR) contrast agent labeled with IRDye800 administered topically to patients with Barrett's esophagus.
Number of subjects: 31
Study 35299780 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplant (aFMT)
Number of subjects: 67
Study 35299780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study 35299970 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose metabolism parameters (including DM, hyperinsulinemia, and insulin resistance)
Number of subjects: 377
Study 35299970 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial 2 h blood glucose ≥11.1mmol/L and HbA1c ≥6.5%
Number of subjects: 377
Study 35299970 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 377
Study 35299970 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher T staging
Number of subjects: 377
Study 35300248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 99
Study 35300248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 35300709 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic training using REAplan® robot for bimanual coordination task (CIRCUIT) over 3 consecutive days.
Number of subjects: 34
Study 35300709 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (HIs) training on the same robotic device.
Number of subjects: 34
Study 35300709 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic training with REAplan® robot.
Number of subjects: 34
Study 35300885 — intervention group
Group type: EXPERIMENTAL
Intervention: Scary Scale (self-assessment fear scale)
Number of subjects: 544
Study 35300897 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO-ICU
Number of subjects: 445
Study 35300897 — intervention group
Group type: COMPARATOR
Intervention: non-ECMO-ICU
Number of subjects: 445
Study 35301040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern Electroretinogram (PERG) stimulation with reversible checkerboards, recorded every 4 weeks for 3 months
Number of subjects: 24
Study 35301040 — intervention group
Group type: EXPERIMENTAL
Intervention: Metric derived from PERG time series using machine learning
Number of subjects: 24
Study 35301040 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at week 12
Number of subjects: 24
Study 35301199 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS demand
Number of subjects: 190
Study 35301199 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS control
Number of subjects: 190
Study 35301199 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for VAS demand and control
Number of subjects: 190
Study 35301199 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS cut-offs
Number of subjects: 190
Study 35301199 — intervention group
Group type: COMPARATOR
Intervention: Comparison of job control
Number of subjects: 190
Study 35301677 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning (DL) based coronary artery calcium scoring (CACS)
Number of subjects: 56
Study 35301822 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg intravitreal injection
Number of subjects: 14
Study 35301985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac ablation
Number of subjects: 80
Study 35301985 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer elevated prior to procedure
Number of subjects: 80
Study 35302268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 109
Study 35302402 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients
Number of subjects: 149
Study 35302402 — intervention group
Group type: EXPERIMENTAL
Intervention: PsO patients
Number of subjects: 149
Study 35302402 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 149
Study 35302581 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 1684
Study 35302581 — intervention group
Group type: EXPERIMENTAL
Intervention: LLDAS
Number of subjects: 1684
Study 35302585 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-382 200-400 mg QD plus pembrolizumab 2 mg/kg IV Q3W (Phase 1b)
Number of subjects: 57
Study 35302585 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-382 300 mg QD plus pembrolizumab 200 mg IV Q3W (Phase 2)
Number of subjects: 57
Study 35302585 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to ARRY-382
Number of subjects: 57
Study 35302622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 99
Study 35302622 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional HRT
Number of subjects: 99
Study 35302622 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (healthy age-matched women)
Number of subjects: 99
Study 35302622 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (young eumenorrheic women)
Number of subjects: 99
Study 35302958 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural processing associated with ventromedial prefrontal cortex activation
Number of subjects: 16
Study 35302958 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management cognitive processes and behaviors
Number of subjects: 16
Study 35302959 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute walk at 100 steps per minute
Number of subjects: 0
Study 35302959 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 35302959 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with knee osteoarthritis
Number of subjects: 0
Study 35302959 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 0
Study 35303007 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T IS quality measurement using ML-based method
Number of subjects: 0
Study 35303007 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-based automated algorithm for quantifying CAR-T IS data
Number of subjects: 0
Study 35303070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg orally twice daily
Number of subjects: 86
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological culture
Number of subjects: 392
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulase-negative staphylococci (CONS)
Number of subjects: 392
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutibacterium acnes
Number of subjects: 392
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infections
Number of subjects: 392
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral surgical approaches
Number of subjects: 392
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Modic changes (MC)
Number of subjects: 392
Study 35303173 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative Oswestry Disability Index (ODI) and Neck Disability Index (NDI)
Number of subjects: 392
Study 35303199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health-focused preventive intervention
Number of subjects: 222
Study 35303201 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) score (0=disability, 6=no disability)
Number of subjects: 2359
Study 35303201 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL as a continuous variable
Number of subjects: 2359
Study 35303201 — intervention group
Group type: EXPERIMENTAL
Intervention: Being 'disabled' (ADL < 6)
Number of subjects: 2359
Study 35303249 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth VIP leadership retreats (large 'kick-off' retreat)
Number of subjects: 0
Study 35303249 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth VIP leadership retreats (smaller, focused retreats during the school year)
Number of subjects: 0
Study 35303249 — intervention group
Group type: COMPARATOR
Intervention: Non-attending youth
Number of subjects: 0
Study 35303285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) in a treat-and-extend regimen
Number of subjects: 210
Study 35303517 — intervention group
Group type: COMPARATOR
Intervention: RNA sequencing for gene expression in males (12 SGA and 27 AGA)
Number of subjects: 74
Study 35303517 — intervention group
Group type: COMPARATOR
Intervention: RNA sequencing for gene expression in females (9 SGA and 26 AGA)
Number of subjects: 74
Study 35303517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-combined analysis
Number of subjects: 74
Study 35303924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) for PPH prevention
Number of subjects: 4521
Study 35304066 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 7839
Study 35304066 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) without AHF
Number of subjects: 7839
Study 35304066 — intervention group
Group type: EXPERIMENTAL
Intervention: AHF without DM
Number of subjects: 7839
Study 35304066 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) and AHF
Number of subjects: 7839
Study 35304622 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg IV on day 1), Apatinib (500 mg oral once daily), S-1 (specific dose oral for first 14 days)
Number of subjects: 24
Study 35304622 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Apatinib, and S-1 combination therapy
Number of subjects: 24
Study 35304684 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab biosimilar PF-06410293 (ADL-PF) 40 mg via prefilled syringe (PFS) and single-use PFP device
Number of subjects: 50
Study 35304729 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue photodynamic disinfection (MB-PDI)
Number of subjects: 0
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ICI/TKI therapy (pembrolizumab, nivolumab, avelumab, or nivolumab-ipilimumab with sunitinib, axitinib, pazopanib, lenvatinib, or cabozantinib)
Number of subjects: 85
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ICI/TKI therapy
Number of subjects: 85
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line ICI/TKI therapy
Number of subjects: 85
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-line or greater ICI/TKI therapy
Number of subjects: 85
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ Second-line ICI/TKI therapy in patients who received ICI only
Number of subjects: 85
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ Second-line ICI/TKI therapy in patients who received both TKI and ICI previously
Number of subjects: 85
Study 35304832 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ Second-line ICI/TKI therapy overall
Number of subjects: 85
Study 35304842 — intervention group
Group type: EXPERIMENTAL
Intervention: Online weight loss intervention
Number of subjects: 43
Study 35305102 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg, day 1) plus paclitaxel (135 mg/m2, day 1) and carboplatin (AUC 5 mg/mL per min, day 1) for 2 cycles
Number of subjects: 20
Study 35305102 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus paclitaxel and carboplatin
Number of subjects: 20
Study 35305254 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira)
Number of subjects: 251
Study 35305260 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 9197
Study 35305260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9197
Study 35305400 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every 3 weeks until loss of clinical benefit or unacceptable toxicity
Number of subjects: 474
Study 35305556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 46
Study 35305556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 46
Study 35305556 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nephrotoxic antibiotic
Number of subjects: 46
Study 35305556 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 46
Study 35305589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lights4Violence intervention
Number of subjects: 1146
Study 35305589 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1146
Study 35305592 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizotypy (measured by Schizotypal Personality Questionnaire - Brief Revised (SPQ-BR))
Number of subjects: 110
Study 35305592 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (measured by Brunnsviken Brief Quality of Life Scale and the European quality of life index version 5D)
Number of subjects: 110
Study 35305592 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic traits (measured by The Ritvo Autism, Asperger Diagnostic Scale-Revised Screen 14 items)
Number of subjects: 110
Study 35305596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg/day)
Number of subjects: 30
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE)
Number of subjects: 1345
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted PCE with updated cohorts
Number of subjects: 1345
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham CVD Lipids
Number of subjects: 1345
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham CVD Body Mass Index (BMI)
Number of subjects: 1345
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Lipids
Number of subjects: 1345
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO BMI
Number of subjects: 1345
Study 35305599 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE model
Number of subjects: 1345
Study 35305740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (Johnson & Johnson), single dose of 5×10^10 viral particles
Number of subjects: 477102
Study 35305850 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department assessment for nonhospitalized injuries
Number of subjects: 2919
Study 35305850 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline determinants of functional decline
Number of subjects: 2919
Study 35305895 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1/mRNA-1273 (8 weeks apart)
Number of subjects: 399
Study 35305895 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1/mRNA-1273 (4 weeks apart)
Number of subjects: 399
Study 35305895 — intervention group
Group type: COMPARATOR
Intervention: ChAdOx1/ChAdOx1 (8 weeks apart)
Number of subjects: 399
Study 35305895 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273/mRNA-1273 (4 weeks apart)
Number of subjects: 399
Study 35305920 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 0
Study 35305920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35306029 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (non-stent)
Number of subjects: 23
Study 35306487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transimpedance Matrix Algorithm for detecting tip fold-over (TFO)
Number of subjects: 157
Study 35306487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transimpedance Matrix Algorithm
Number of subjects: 157
Study 35306524 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological stimulation
Number of subjects: 0
Study 35306524 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid administration
Number of subjects: 0
Study 35306553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine ≥4 g/day
Number of subjects: 151
Study 35306553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine treatment duration >6 months
Number of subjects: 151
Study 35306553 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine treatment duration 3-6 months
Number of subjects: 151
Study 35306553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine treatment
Number of subjects: 151
Study 35306594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac-CoronaVac vaccine (two doses 28 days apart, D0/D28)
Number of subjects: 51
Study 35307611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 1)
Number of subjects: 109
Study 35307611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 2)
Number of subjects: 109
Study 35307611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily in continuous 21-day cycles
Number of subjects: 109
Study 35307761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern 1 (high in discretionary foods and saturated fatty acids, low in fibre)
Number of subjects: 1280
Study 35307761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern 2 (positively correlated with discretionary foods and SFA)
Number of subjects: 1280
Study 35307761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern 3 (positively correlated with SFA and fibre)
Number of subjects: 1280
Study 35307761 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO risk genotype
Number of subjects: 1280
Study 35307972 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, axitinib, and palbociclib (DL1: avelumab 10 mg/kg IV q2weeks, axitinib 3 mg po bid, palbociclib 75 mg po daily for 7 days off/21 days on)
Number of subjects: 15
Study 35307972 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, axitinib, and palbociclib (DL1)
Number of subjects: 15
Study 35307972 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, axitinib, and palbociclib combination
Number of subjects: 15
Study 35308034 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL of convalescent plasma (Low-volume)
Number of subjects: 129
Study 35308034 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL of convalescent plasma (High-volume)
Number of subjects: 129
Study 35308034 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 129
Study 35308099 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) prophylaxis administered intravenously for up to 104 weeks, every 7 days, twice weekly, or three times weekly.
Number of subjects: 160
Study 35308099 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) prophylaxis
Number of subjects: 160
Study 35308376 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP treatment (once-weekly rifapentine plus isoniazid for 3 months)
Number of subjects: 80
Study 35308535 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 40 mg intravenous dexamethasone
Number of subjects: 24
Study 35308535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 35308563 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based intervention (MAP intervention)
Number of subjects: 0
Study 35308563 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based intervention (MAC intervention)
Number of subjects: 0
Study 35308563 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based intervention (combined MAP/MAC)
Number of subjects: 0
Study 35308563 — intervention group
Group type: COMPARATOR
Intervention: EEG-blinded standard anaesthesia (control)
Number of subjects: 0
Study 35309052 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min active stand (AS) with Finapres
Number of subjects: 0
Study 35309087 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcenestrant 200 mg plus palbociclib 125 mg
Number of subjects: 1066